தொற்றுநோய் தகவல்கள் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தொற்றுநோய் தகவல்கள் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தொற்றுநோய் தகவல்கள் மையம் Today - Breaking & Trending Today

NIMH » Questions and Answers for the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Study — Background

March 2007
A. STEP-BD is the largest, federally-funded treatment study ever conducted for bipolar disorder
1. It is a long-term outpatient study that enrolled 4,360 participants from 22 sites over seven years (1998 to 2005). STEP-BD was designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. STEP-BD is different from typical clinical trials that test one potential new treatment. It is a broad research program that includes several different studies, each aimed at a different aspect of treatment for the illness.
Multiple treatments, including medications and psychotherapies, currently are available for people with bipolar disorder, but doctors are often uncertain which of these treatments actually work best for specific aspects of the illness. ....

United States , San Antonio , Baylor College Of Medicine , University Of Massachusetts Medical School , University Of Pennsylvania , Stephenr Wisniewski , Laurenb Marangell , Lamotrigine Lamictal , Jayendra Patel , Garys Sachs , Markd Fossey , Laszlo Gyulai , Terencea Ketter , Marks Bauer , Charles Bowden , Risperidone Risperdal , Peter Hauser , Paroxetine Paxil , Smith Kline , Josephr Calabrese , Kemal Sagduyu , Andrewa Nierenberg , Michael Allen , Systematic Treatment Enhancement Program For Bipolar Disorder , Harvard School Of Medicine , Stanford University School Of Medicine ,

NIMH » Questions and Answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study — Background

January 2006
1. What is the STAR D study?
A. The Sequenced Treatment Alternatives to Relieve Depression (STAR D) Study, funded by the NIH National Institute of Mental Health, is a nationwide public health clinical trial. The purpose of the trial is to determine the effectiveness of different treatments for people with Major Depressive Disorder (MDD) who have not responded to initial treatment with an antidepressant. This is the largest and longest study ever done to evaluate depression treatment. Over a seven-year period, the study enrolled more than 4,000 outpatients, aged 18-75 years. The participants were people who came to their doctors for care and who had other psychiatric and medical conditions like those regularly seen in typical clinical practices (see Ref 1). Patients from both mental health (specialty care) and non-mental health (primary medical care) practices in diverse racial, ethnic, and socioeconomic populations were enrolled in the study. ....

United States , University Of Texas Southwestern Medical Center , University Of Texas , Andrew Leuchter , Buspirone Buspar , Sidney Zisook , Richard Shelton , William Gilmer , Brad Gaynes , Melanie Biggs , Jonathan Alpert , Fred Quitkin , Tranylcypromine Parnate , Madhukar Trivedi , Susan Kornstein , Stephen Wisniewski , Robert Golden , Mustafa Husain , Jeff Mitchell , Sheldon Preskorn , Citalopram Celexa , Edward Friedman , Andrew Nierenberg , Steven Hollon , Nortriptyline Pamelor , Diane Stegman ,